DK0996468T3 - Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika - Google Patents
Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesikaInfo
- Publication number
- DK0996468T3 DK0996468T3 DK98946571T DK98946571T DK0996468T3 DK 0996468 T3 DK0996468 T3 DK 0996468T3 DK 98946571 T DK98946571 T DK 98946571T DK 98946571 T DK98946571 T DK 98946571T DK 0996468 T3 DK0996468 T3 DK 0996468T3
- Authority
- DK
- Denmark
- Prior art keywords
- galactose
- pain
- agents
- analgesics
- conjugates
- Prior art date
Links
- 241001112695 Clostridiales Species 0.000 title 1
- 102000004856 Lectins Human genes 0.000 title 1
- 108090001090 Lectins Proteins 0.000 title 1
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 229930182830 galactose Natural products 0.000 title 1
- 239000002523 lectin Substances 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 102000007563 Galectins Human genes 0.000 abstract 1
- 108010046569 Galectins Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721189.0A GB9721189D0 (en) | 1997-10-08 | 1997-10-08 | Analgesic conjugates |
| PCT/GB1998/003001 WO1999017806A1 (en) | 1997-10-08 | 1998-10-07 | Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0996468T3 true DK0996468T3 (da) | 2003-09-15 |
Family
ID=10820129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98946571T DK0996468T3 (da) | 1997-10-08 | 1998-10-07 | Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7052702B1 (da) |
| EP (1) | EP0996468B1 (da) |
| JP (1) | JP4629225B2 (da) |
| AT (1) | ATE240747T1 (da) |
| AU (1) | AU741456B2 (da) |
| CA (1) | CA2306350C (da) |
| DE (1) | DE69814858T2 (da) |
| DK (1) | DK0996468T3 (da) |
| ES (1) | ES2198750T3 (da) |
| GB (1) | GB9721189D0 (da) |
| PT (1) | PT996468E (da) |
| WO (1) | WO1999017806A1 (da) |
| ZA (1) | ZA989138B (da) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
| US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
| DE60032367T3 (de) | 1999-08-25 | 2011-03-10 | Allergan, Inc., Irvine | Aktivierbare rekombinante neurotoxine |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) * | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| EP1234043B1 (en) * | 1999-12-02 | 2004-03-10 | Health Protection Agency | Constructs for delivery of therapeutic agents to neuronal cells |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| AU4904101A (en) * | 1999-12-08 | 2001-07-09 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
| US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6641820B1 (en) * | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| JP2004521067A (ja) * | 2000-06-28 | 2004-07-15 | サンダース，イラ | 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法 |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| GB0108332D0 (en) * | 2001-04-03 | 2001-05-23 | Univ Durham | Lectin directed prodrug delivery system |
| US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| DE602005011458D1 (de) * | 2004-09-01 | 2009-01-15 | Allergan Inc | Abbaubare clostridientoxine |
| US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
| US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| WO2006099590A2 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| EP2505592A1 (en) | 2006-07-11 | 2012-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| CA2658260A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| NZ585108A (en) * | 2007-10-23 | 2012-09-28 | Allergan Inc | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
| WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| PT2854840T (pt) | 2012-05-30 | 2018-03-02 | Harvard College | Neurotoxina botulínica geneticamente modificada |
| US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| CN111454931A (zh) * | 2012-11-21 | 2020-07-28 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| HK1248737A1 (zh) | 2015-03-26 | 2018-10-19 | 哈佛大学校长及研究员协会 | 工程改造的肉毒杆菌神经毒素 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| EP3529616B1 (en) | 2016-10-20 | 2023-09-06 | President and Fellows of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
| JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| BR112023018473A2 (pt) | 2021-03-30 | 2023-11-14 | Ipsen Biopharm Ltd | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios |
| BR112023020057A2 (pt) | 2021-03-30 | 2024-03-12 | Ipsen Biopharm Ltd | Tratamento de dor e distúrbios inflamatórios |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792447A (en) | 1981-07-23 | 1988-12-20 | Board Of Regents, The University Of Texas System | Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4873346A (en) | 1985-09-20 | 1989-10-10 | The Upjohn Company | Substituted benzothiazoles, benzimidazoles, and benzoxazoles |
| AU657087B2 (en) | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| AU1582692A (en) | 1991-03-08 | 1992-10-06 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
| WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
| US5433946A (en) | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| DE4242902A1 (de) | 1992-12-18 | 1994-06-23 | Madaus Ag | Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie |
| JP4249802B2 (ja) | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
| EP1488803B1 (en) | 1993-12-28 | 2008-03-26 | Allergan, Inc. | Neurotoxic component of botulinum toxins for treating cervical dystonia |
| JP3497554B2 (ja) | 1994-03-25 | 2004-02-16 | 日本臓器製薬株式会社 | 新規プリン誘導体及びその薬学的に許容される塩 |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| ES2138740T3 (es) * | 1994-05-31 | 2000-01-16 | Allergan Inc | Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| CN1176658A (zh) | 1994-10-24 | 1998-03-18 | 蛇药制品有限公司 | 治疗和预防艰难梭菌疾病的疫苗和抗毒素 |
| US5721207A (en) * | 1995-04-18 | 1998-02-24 | Innapharma, Inc. | Method for treatment of pain |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| WO1997013410A1 (en) | 1995-10-13 | 1997-04-17 | Boston Medical Center Corporation | Hybrid molecules containing amidated polypeptide binding ligands |
| JP2000503630A (ja) * | 1995-11-22 | 2000-03-28 | ザ リサーチ アンド ディベロップメント インスティチュート，インコーポレイテッド | 微生物感染症の治療用治療剤及び診断剤 |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US5760149A (en) | 1996-08-23 | 1998-06-02 | Elf Atochem North America, Inc. | Poly(monoperoxycarbonates) |
| WO1998008540A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
| DE19735105A1 (de) | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CZ294376B6 (cs) | 1998-05-13 | 2004-12-15 | Biotecon Gesellschaft Für Biotechnologische Entwic | Hybridní protein a léčivo pro inhibici degranulace žírných buněk |
| DK1346731T3 (da) | 1998-07-22 | 2007-04-10 | Osprey Pharmaceuticals Ltd | Konjugater til behandling af inflammatoriske forstyrrelser og tilsvarende vævsskade |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
| GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
-
1997
- 1997-10-08 GB GBGB9721189.0A patent/GB9721189D0/en not_active Ceased
-
1998
- 1998-10-07 JP JP2000514674A patent/JP4629225B2/ja not_active Expired - Fee Related
- 1998-10-07 US US09/529,130 patent/US7052702B1/en not_active Expired - Fee Related
- 1998-10-07 DE DE69814858T patent/DE69814858T2/de not_active Expired - Lifetime
- 1998-10-07 PT PT98946571T patent/PT996468E/pt unknown
- 1998-10-07 ZA ZA989138A patent/ZA989138B/xx unknown
- 1998-10-07 WO PCT/GB1998/003001 patent/WO1999017806A1/en not_active Ceased
- 1998-10-07 EP EP98946571A patent/EP0996468B1/en not_active Expired - Lifetime
- 1998-10-07 CA CA002306350A patent/CA2306350C/en not_active Expired - Fee Related
- 1998-10-07 AU AU93574/98A patent/AU741456B2/en not_active Ceased
- 1998-10-07 AT AT98946571T patent/ATE240747T1/de not_active IP Right Cessation
- 1998-10-07 DK DK98946571T patent/DK0996468T3/da active
- 1998-10-07 ES ES98946571T patent/ES2198750T3/es not_active Expired - Lifetime
-
2005
- 2005-10-25 US US11/257,500 patent/US7452543B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69814858T2 (de) | 2004-03-11 |
| EP0996468B1 (en) | 2003-05-21 |
| JP2001518522A (ja) | 2001-10-16 |
| ZA989138B (en) | 1999-05-27 |
| CA2306350A1 (en) | 1999-04-15 |
| PT996468E (pt) | 2003-09-30 |
| ATE240747T1 (de) | 2003-06-15 |
| WO1999017806A1 (en) | 1999-04-15 |
| US7052702B1 (en) | 2006-05-30 |
| AU741456B2 (en) | 2001-11-29 |
| US7452543B2 (en) | 2008-11-18 |
| US20060121056A1 (en) | 2006-06-08 |
| GB9721189D0 (en) | 1997-12-03 |
| ES2198750T3 (es) | 2004-02-01 |
| DE69814858D1 (de) | 2003-06-26 |
| JP4629225B2 (ja) | 2011-02-09 |
| AU9357498A (en) | 1999-04-27 |
| CA2306350C (en) | 2008-09-02 |
| EP0996468A1 (en) | 2000-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE240747T1 (de) | Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika | |
| AR024306A1 (es) | Preparacion farmaceutica que contiene una neurotoxina botulinica. | |
| ATE298791T1 (de) | Protease-varianten und zusammensetzungen | |
| MXPA03000576A (es) | Motivo a base de leucina y neurotoxinas clostridial. | |
| PT1311504E (pt) | Tetrazolil-fenil-acetamidas activadoras da glucoquinase | |
| DK0819135T3 (da) | Kulhydratmodificerede cytostatika | |
| EP0945750A3 (en) | Polarizing beam splitter/combiner | |
| ATE413386T1 (de) | Ppar-gamma modulatoren | |
| DE69518001D1 (de) | Naphthalinboronsäuren | |
| EA200200105A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ; | |
| FR2790765B1 (fr) | Milieu chromogene de detection de staphylococcus aureus. | |
| DE60023107D1 (de) | Zubereitungen mit verbesserter kontrollierter freisetzung | |
| DK1234043T3 (da) | Konstruktion for afgivelse af terapeutiske midler til neuroceller | |
| AU2003295769A1 (en) | Treatment of mammalian reaction to ige interactions | |
| ATE310968T1 (de) | Lichtleiterkupplung | |
| BR9911619A (pt) | Pestivìrus atenuados | |
| ATE384975T1 (de) | Optischer isolator mit niedrigen einfügeverlusten und minimierter polarisationsmodendispersion | |
| NO980923D0 (no) | Optisk aktivt fenylpyrimidin-derivat som analgetisk middel | |
| ATE320422T1 (de) | Metalloproteinase inhibitoren | |
| YU31697A (sh) | Varijante aprotinina sa poboljšanim svojstvima | |
| NO904876L (no) | Optisk forsterker med aktiv fiber og bredt pumpingsbaand, og beslektet optisk fiber. | |
| DK0752102T3 (da) | Immunoenzymatisk konjugat, fremgangsmåde til fremstilling af konjugatet og anvendelse af dette. | |
| DE59605990D1 (de) | Anschlussvorrichtung für anschlagmittel | |
| AU1885700A (en) | Device for holding socks or stockings in pairs | |
| DE69604117D1 (de) | Optisch aktive Dihydropyranderivate, Flüssigkristallzusammensetzung, Flüssigkristallvorrichtung, Flüssigkristallracematmischung |